BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 23480103)

  • 1. In vitro assessment of buffy-coat derived platelet components suspended in SSP+ treated with the INTERCEPT Blood system.
    Johnson L; Loh YS; Kwok M; Marks DC
    Transfus Med; 2013 Apr; 23(2):121-9. PubMed ID: 23480103
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro assessment of apheresis and pooled buffy coat platelet components suspended in plasma and SSP+ photochemically treated with amotosalen and UVA for pathogen inactivation (INTERCEPT Blood System™).
    Chavarin P; Cognasse F; Argaud C; Vidal M; De Putter C; Boussoulade F; Ripaud C; Acquart S; Lin L; Garraud O
    Vox Sang; 2011 Feb; 100(2):247-9. PubMed ID: 20735811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional characteristics of apheresis-derived platelets treated with ultraviolet light combined with either amotosalen-HCl (S-59) or riboflavin (vitamin B2) for pathogen-reduction.
    Picker SM; Oustianskaia L; Schneider V; Gathof BS
    Vox Sang; 2009 Jul; 97(1):26-33. PubMed ID: 19302416
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of pathogen reduction technology (Mirasol) on platelet quality when treated in additive solution with low plasma carryover.
    Johnson L; Winter KM; Reid S; Hartkopf-Theis T; Marschner S; Goodrich RP; Marks DC
    Vox Sang; 2011 Oct; 101(3):208-14. PubMed ID: 21492184
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preserved functional and biochemical characteristics of platelet components prepared with amotosalen and ultraviolet A for pathogen inactivation.
    Hechler B; Ohlmann P; Chafey P; Ravanat C; Eckly A; Maurer E; Mangin P; Isola H; Cazenave JP; Gachet C
    Transfusion; 2013 Jun; 53(6):1187-200. PubMed ID: 23067365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Implementation of the INTERCEPT Blood System for Platelets into routine blood bank manufacturing procedures: evaluation of apheresis platelets.
    Janetzko K; Lin L; Eichler H; Mayaudon V; Flament J; Klüter H
    Vox Sang; 2004 May; 86(4):239-45. PubMed ID: 15144528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cryopreservation of buffy-coat-derived platelet concentrates in dimethyl sulfoxide and platelet additive solution.
    Johnson LN; Winter KM; Reid S; Hartkopf-Theis T; Marks DC
    Cryobiology; 2011 Apr; 62(2):100-6. PubMed ID: 21241687
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro cell quality of buffy coat platelets in additive solution treated with pathogen reduction technology.
    Ostrowski SR; Bochsen L; Salado-Jimena JA; Ullum H; Reynaerts I; Goodrich RP; Johansson PI
    Transfusion; 2010 Oct; 50(10):2210-9. PubMed ID: 20456708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimized processing for pathogen inactivation of double-dose buffy-coat platelet concentrates: maintained in vitro quality over 7-day storage.
    Ohlsson S; Diedrich B; Uhlin M; Sandgren P
    Vox Sang; 2018 Oct; 113(7):611-621. PubMed ID: 30156292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of in vitro storage properties of prestorage pooled whole blood-derived platelets suspended in 100 percent plasma and treated with amotosalen and long-wavelength ultraviolet light.
    Wagner SJ; Skripchenko A; Myrup A; Awatefe H; Thompson-Montgomery D; Moroff G; Carmichael P; Lin L
    Transfusion; 2009 Apr; 49(4):704-10. PubMed ID: 19171001
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extended storage of platelets in SSP platelet additive solution.
    Hornsey VS; McColl K; Drummond O; McMillan L; Morrison A; Morrison L; MacGregor IR; Prowse CV
    Vox Sang; 2006 Jul; 91(1):41-6. PubMed ID: 16756600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro storage characteristics of platelet concentrates suspended in 70% SSP+(TM) additive solution versus plasma over a 14-day storage period.
    Saunders C; Rowe G; Wilkins K; Holme S; Collins P
    Vox Sang; 2011 Aug; 101(2):112-21. PubMed ID: 21414010
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Mirasol Pathogen Reduction Technology system and quality of platelets stored in platelet additive solution.
    Reikvam H; Marschner S; Apelseth TO; Goodrich R; Hervig T
    Blood Transfus; 2010 Jul; 8(3):186-92. PubMed ID: 20671879
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro effects on platelets irradiated with short-wave ultraviolet light without any additional photoactive reagent using the THERAFLEX UV-Platelets method.
    Sandgren P; Tolksdorf F; Struff WG; Gulliksson H
    Vox Sang; 2011 Jul; 101(1):35-43. PubMed ID: 21175668
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Platelet derived cytokine accumulation in platelet concentrates treated for pathogen reduction.
    Tauszig ME; Picker SM; Gathof BS
    Transfus Apher Sci; 2012 Feb; 46(1):33-7. PubMed ID: 22119364
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Generation of procoagulant collagen- and thrombin-activated platelets in platelet concentrates derived from buffy coat: the role of processing, pathogen inactivation, and storage.
    Bertaggia Calderara D; Crettaz D; Aliotta A; Barelli S; Tissot JD; Prudent M; Alberio L
    Transfusion; 2018 Oct; 58(10):2395-2406. PubMed ID: 30229925
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Storage of buffy-coat-derived platelets in additive solutions at 4 degrees C and 22 degrees C: flow cytometry analysis of platelet glycoprotein expression.
    Sandgren P; Hansson M; Gulliksson H; Shanwell A
    Vox Sang; 2007 Jul; 93(1):27-36. PubMed ID: 17547562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathogen inactivation of double-dose buffy-coat platelet concentrates photochemically treated with amotosalen and UVA light: preservation of in vitro function.
    Sandgren P; Diedrich B
    Vox Sang; 2015 May; 108(4):340-9. PubMed ID: 25557354
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolomic analysis of platelets during storage: a comparison between apheresis- and buffy coat-derived platelet concentrates.
    Paglia G; Sigurjónsson ÓE; Rolfsson Ó; Hansen MB; Brynjólfsson S; Gudmundsson S; Palsson BO
    Transfusion; 2015 Feb; 55(2):301-13. PubMed ID: 25156572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Platelet storage lesion in interim platelet unit concentrates: A comparison with buffy-coat and apheresis concentrates.
    Singh S; Shams Hakimi C; Jeppsson A; Hesse C
    Transfus Apher Sci; 2017 Dec; 56(6):870-874. PubMed ID: 29126740
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.